Edition:
United States

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

16.33USD
23 Feb 2018
Change (% chg)

$1.08 (+7.08%)
Prev Close
$15.25
Open
$15.39
Day's High
$16.36
Day's Low
$15.39
Volume
20,676
Avg. Vol
--
52-wk High
$25.33
52-wk Low
$12.51

Chart for

About

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The... (more)

Overall

Beta: --
Market Cap(Mil.): $821.96
Shares Outstanding(Mil.): 50.33
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

BRIEF-Apellis Pharmaceuticals Announces 18-Month Results Of Phase 2 Study Of APL-2 In Geographic Atrophy

* APELLIS PHARMACEUTICALS ANNOUNCES 18-MONTH RESULTS OF PHASE 2 STUDY (FILLY) OF APL-2 IN GEOGRAPHIC ATROPHY Source text for Eikon: Further company coverage:

Feb 22 2018

BRIEF-Apellis Finalizes Late Stage Trial Plans For Eye Disease Treatment

* APELLIS FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR GEOGRAPHIC ATROPHY TREATMENT WITH APL-2

Dec 20 2017

BRIEF-Apellis Pharmaceuticals Appoints Timothy Sullivan as CFO

* APELLIS PHARMACEUTICALS EXPANDS MANAGEMENT TEAM, APPOINTS TIMOTHY SULLIVAN CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

Dec 19 2017

BRIEF-Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc

* Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing Source text (http://bit.ly/2jcJaxu) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Nov 21 2017

Earnings vs. Estimates